Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic doses of efzofitimod demonstrate efficacy in pulmonary sarcoidosis.
Obi ON, Baughman RP, Crouser ED, Julian MW, Locke LW, Chandrasekaran A, Ramesh P, Kinnersley N, Niranjan V, Culver DA, Sporn PHS. Obi ON, et al. Among authors: culver da. ERJ Open Res. 2025 Jan 13;11(1):00536-2024. doi: 10.1183/23120541.00536-2024. eCollection 2025 Jan. ERJ Open Res. 2025. PMID: 39811550 Free PMC article.
Race and class in big data.
Harper L, Culver DA, Cozier YC. Harper L, et al. Among authors: culver da. Sarcoidosis Vasc Diffuse Lung Dis. 2024 Jun 28;41(2):e2024001. doi: 10.36141/svdld.v41i2.16149. Sarcoidosis Vasc Diffuse Lung Dis. 2024. PMID: 38940705 Free PMC article. No abstract available.
Proportion and predictors of FVC decline in patients with interstitial lung disease.
Macmurdo MG, Ji X, Pimple P, Olson AL, Milinovich A, Martyn-Dow B, Pande A, Zajichek A, Bauman J, Bender S, Conoscenti C, Sugano D, Kattan MW, Culver DA. Macmurdo MG, et al. Among authors: culver da. Respir Med. 2024 Jun;227:107656. doi: 10.1016/j.rmed.2024.107656. Epub 2024 Apr 30. Respir Med. 2024. PMID: 38697229 Free article.
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
Frank I, Li SS, Grunenberg N, Overton ET, Robinson ST, Zheng H, Seaton KE, Heptinstall JR, Allen MA, Mayer KH, Culver DA, Keefer MC, Edupuganti S, Pensiero MN, Mehra VL, De Rosa SC, Morris DE, Wang S, Seaman MS, Montefiori DC, Ferrari G, Tomaras GD, Kublin JG, Corey L, Lu S; HVTN 124 Study Team. Frank I, et al. Among authors: culver da. Lancet HIV. 2024 May;11(5):e285-e299. doi: 10.1016/S2352-3018(24)00036-5. Lancet HIV. 2024. PMID: 38692824 Clinical Trial.
197 results